



Intended Audience

Updates in Inflammatory Bowel Disease 2017 is the 9th University of Maryland School of Medicine Division of Gastroenterology and Hepatology Symposium. This in-depth symposium will focus on treating patients with IBD and is intended for practicing gastroenterologists, surgeons, nurse practitioners, physician assistants, nurses, dieticians, and scientists. The presentations, discussion periods and interactive formats are intended to stimulate audience participation in the discussion of these timely topics.

Symposium Co-Directors

Raymond K. Cross, M.D., M.S., A.G.A.F.

Professor of Medicine and Director of the Inflammatory Bowel Disease Program of the Division of Gastroenterology and Hepatology at the University of Maryland School of Medicine and Co-Director of the Digestive Health Center University of Maryland Medical Center. His clinical research interests are focused on the optimization of patient outcomes using telemedicine systems, disparities in care of patients with inflammatory bowel disease, and in the design and implementation of clinical trials. He is a physician member of the Crohn's and Colitis Foundation and is Chairman of the Clinical Awards Committee of the Crohn's and Colitis Foundation of America.

Sandra M. Quezada, M.D., M.S. Assistant Professor of Medicine of the Division of Gastroenterology and Hepatology and Assistant Dean of Admissions at the University of Maryland School of Medicine. Her clinical research interest are include differences in disease characteristics in older patients with IBD, optimizing treatment outcomes and implementation of medical Spanish into student teaching. She is a Member of the Mission Committee of the Maryland and Southern Delaware Chapter of the Crohn's and Colitis Foundation of America.

Faculty

The faculty for this CME-accredited symposium represents a combination of distinguished clinician investigators in the Division of Gastroenterology and Hepatology as well as the Division of General and Oncologic Surgery and Pediatric Gastroenterology at the University of Maryland School of Medicine. Experts of reknown from other medical schools include the University of Pittsburgh Medical Center, University of North Carolina School of Medicine – Chapel Hill, Mayo Clinic and Brigham and Women's Hospital.

Hotel Accommodations


If you plan to stay in Baltimore for the conference, the following hotel is offering the University of Maryland Rate and is in walking distance to the campus center

Hilton Baltimore Hotel – Rate \$159 per night (plus city/state tax)
401 W. Pratt Street, Baltimore, Maryland 21201
Ph.# 443-573-8714 **When reserving, please mention the SRP Code IBD.
Room availability is dependent upon the Hilton Baltimore Hotel.
To reserve a room on-line:
<https://aws.passkey.com/go/IBDConference2017>

Reservations for all guests must be received on or before Tuesday, April 26, 2017, (the Cut-off Date). The Hilton Baltimore Hotel is within walking distance of the Babe Ruth Museum, Oriole Park, Sports Legends Museum, as well as Baltimore's famous Inner Harbor, the Hippodrome Theater, fashionable shopping, and world-class dining.

For more on what's happening in and around Baltimore, please visit www.baltimore.org

Presorted Standard
US Postage
PAID
Timonium, MD
Permit No. 90



Updates in Inflammatory
Bowel Disease



Friday, May 26, 2017



UNIVERSITY of MARYLAND

Invites You to Attend

Updates in Inflammatory
Bowel Disease



Friday, May 26, 2017

University of Maryland

Southern Management Corporation Campus Center
621 West Lombard Street • Baltimore, Maryland 21201

Presented by
University of Maryland School of Medicine

Location: Southern Management Corporation Campus Center 621 W. Lombard Street, Baltimore, Maryland 21201. The SMC Campus Center is situated between the Health Science Library and the University of Maryland School of Nursing.

Registration Fee: Includes instruction materials, meals, CME certificate, and complimentary parking at the Pratt Street Garage.

Driving Directions:

From the North or South: Follow 195 to exit 52 (Russell Street). Follow Russell as it merges into Paca Street. Turn left onto Lombard St. and cross over Greene St. and the campus center will be on the left.

From I-83: Follow I-83 (Jones Falls Expressway) until expressway ends. Go two traffic lights and turn right onto Lombard Street. Follow Lombard Street for 13 traffic lights and right after crossing over Greene St., the campus center will be on the left.

Parking: Complimentary parking is available at the Pratt Street Garage located at 646 W. Pratt Street, Baltimore, Maryland 21201. Please bring your parking voucher to registration for validation.

Faculty

UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE FACULTY

Raymond K. Cross, M.D., M.S.
- Course Co-Director -

*Professor of Medicine
Director, Inflammatory Bowel Disease Program
Division of Gastroenterology and Hepatology
Co-Director, Digestive Health Center
University of Maryland Medical Center*

Nidhi Malhotra, M.D.

*Clinical Instructor of Medicine
Division of Gastroenterology and Hepatology*

Shelley Nehman, RD

*Clinical Dietitian
Digestive Health Center
University of Maryland Medical Center*

Sandra M. Quezada, M.D., M.S.
- Course Co-Director -

*Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
Assistant Dean of Admissions*

Seema A. Patil, M.D.

*Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
Director, Gastroenterology and Hepatology
Fellowship Program*

Andrea Chao Bafford, M.D.

*Assistant Professor of Surgery
Department of Surgery
Division of General and Oncologic Surgery*

Uni Wong, M.D.

*Gastroenterology Fellow
Division of Gastroenterology and Hepatology*

VISITING FACULTY

Joshua Korzenik, M.D.

*Assistant Professor of Medicine
Harvard Medical School
Director of Crohn's and Colitis Center
Brigham and Women's Hospital*

Millie Long, M.D., M.P.H.

*Associate Professor of Medicine
University of North Carolina, School of Medicine*

Miguel D. Regueiro, M.D.

*Professor of Medicine
IBD Clinical Medical Director
Associate Chief for Education
Senior Medical Lead of Specialty Medical Homes
Co-Director, Total Care-IBD
University of Pittsburgh Medical Center*

Edward V. Loftus, Jr., M.D.

*Professor of Medicine
Director, Inflammatory Bowel Disease Interest Group
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester MN*

ACCREDITATION

The University of Maryland School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT STATEMENT

The University of Maryland School of Medicine designates this Live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity..

FACULTY DISCLOSURE

It is the policy of the University of Maryland School of Medicine to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, all persons in a position to control the educational content of this activity must disclose any relevant financial relationships they have with commercial interests. Any identified conflicts of interest must be resolved prior to the speaker's presentation.

AMERICANS WITH DISABILITIES ACT

If you require special accommodations to attend or participate in this CME activity, please provide information about your requirements to Gloria Owens at 410-706-3956 or (1-800-735-2258 TTY/Voice) at least five business days in advance of the activity.

RESERVATION CANCELLATION POLICY

If you require special accommodations to attend or participate in this CME activity, please provide information about your requirements to Gloria Owens at 410-706-3956 or (1-800-735-2258 TTY/Voice) at least five business days in advance of the activity.

Agenda

7:15-8:00 a.m.

Registration and Breakfast

8:00-8:15 a.m.

Welcome and Introduction

Raymond Cross, M.D., M.S.

8:15-8:30 a.m.

Identifying Patients at High Risk for a Severe Disease Course

Edward V. Loftus, Jr., M.D.

8:30-8:45 a.m.

Positioning Biologic Therapy Patients with IBD

Josh Korzenik, M.D.

8:45-9:00 a.m.

Management of Patients with Complicated Disease

Seema Patil, M.D.

9:00-9:15 a.m.

Selection of Therapies in IBD Patients with Comorbid Conditions

Millie Long, M.D., M.P.H.

9:15-10:00 a.m.

Case Presentations and Discussion

Raymond Cross, M.D., M.S. Andrea Bafford, M.D. and Faculty

10:00-10:30 a.m.

Break and Case Discussion

Raymond Cross, M.D., M.S. and Faculty

10:30-10:45 a.m.

Optimizing 5-ASA and Steroids in Patients with Ulcerative Colitis

Sandra Quezada, M.D., M.S.

10:45-11:00 a.m.

Optimal Use of Therapeutic Drug Monitoring in IBD Practice

Josh Korzenik, M.D.

11:00-11:15 p.m.

Prevention of Post-operative Crohn's Disease

Miguel Regueiro, M.D.

11:15-11:30 p.m.

Healing the Bowel. Is it Needed and How Do You Do It?

Raymond Cross, M.D., M.S.

11:30-12:15 p.m.

Case Presentations and Discussion

Sandra Quezada, M.D., M.S., Nidhi Malhotra, M.D. and Faculty

12:15-1:00 p.m.

Lunch

1:00-1:30 p.m.

Keynote Lecture: Emerging Therapies in IBD

Edward V. Loftus, Jr., M.D.

1:30-1:45 p.m.

Women's Health in IBD

Millie Long, M.D., M.P.H.

1:45-2:00 p.m.

Prevention and Identification of Infectious Complications in Patients with IBD

Miguel Regueiro, M.D.

2:00-2:15 p.m.

SCENIC Guidelines: Implementation in Practice

Raymond Cross, M.D., M.S.

2:15-2:30 p.m.

I Have IBD. What Can I Eat?

Sandra Quezada, M.D., M.S.

2:30-3:15 p.m.

Case Presentations and Discussion

Seema Patil, M.D., Uni Wong, M.D., Shelley Nehman, RD and Faculty

3:15 p.m.

Closing Remarks

Raymond Cross, M.D., M.S.

Course Description

Inflammatory bowel disease (IBD), comprised of ulcerative colitis (UC) and Crohn's disease (CD), affects over 1.8 million patients in the United States. Both diseases are chronic, characterized by periodic exacerbations of symptoms, and have a negative impact on quality of life. These diseases are associated with significant direct and indirect health care costs. Despite advances in medical treatment, including the recent approval of new therapeutic agents for the treatment of IBD, outcomes are still suboptimal in a significant subset of patients. Poor outcomes of treatment can result in complications of disease, need for surgery and excess health care utilization. New care pathways have been developed to assist providers in risk stratifying patients so that patients likely to have a severe disease course receive more aggressive treatment. There is still debate regarding optimal treatment in both patients at low and high risk for a severe disease course. For example, providers must choose between several anti-TNF, anti-integrin, and anti-IL 12/23 agents for patients at high risk for a severe disease course. They also must consider whether patients should be treated with concurrent immune suppression. These decisions will become more difficult in the next 5 years as it is anticipated that several new therapies will be approved for the treatment of IBD. With increased use of biologic treatment, concerns over safety and cost persist. Management of patients with complicated IBD including but not limited to those with perianal involvement and stricturing or penetrating disease continues to be a challenge. In addition, management of subsets of patients with IBD including adolescents, child-bearing age women, the elderly and those with co-morbid conditions can be daunting. Once treatment is initiated, methods to optimize therapy such as drug monitoring continue to be explored. In addition, new outcomes measures are being proposed to assess the efficacy of treatment including surrogate markers of inflammation such as fecal calprotectin, c reactive protein and mucosal healing. Health prevention is another important aspect in the care of patients with IBD, particularly those receiving immune suppressants or biologic therapies. Screening for colon cancer is recommended in patients with chronic colitis to prevent this dreaded complication. Dysplasia is often a precursor to cancer in patients with chronic colitis. New guidelines have been developed to utilize advanced endoscopic techniques for identification and management of dysplasia in patients with chronic colitis.

Given that IBD is common and there is debate regarding the optimal use of therapeutic agents and management of patients with complicated disease, this one day symposium highlights the management of patients with these disorders.

Course Objectives

At the conclusion of this activity, participants will be able to:

- Identify patients with inflammatory bowel disease at increased risk for a severe disease course
- Select the most appropriate treatment for a patient with inflammatory bowel disease based on personal and clinical characteristics and disease history.
- Manage patients with complicated inflammatory bowel disease including those patients with perianal involvement, co-morbid medical conditions, stricturing or penetrating disease and those that are refractory to treatment.

First Name	MI	Last Name	Degree
Complete Mailing Address			
City, State, Zip Code			
Business Telephone			
E-Mail Address			
REGISTRATION FEE	<input type="checkbox"/> Physicians (MD, DO) \$100.00	<input type="checkbox"/> Other Healthcare Professionals \$50.00	<input type="checkbox"/> UM/C Fellows/Residents/Complimentary
TOTAL AMOUNT ENCLOSED	Make Check Payable to: UNIVERSITY OF MARYLAND		
Or you may pay by MasterCard or VISA			
Cardholder's Name	(PRINT CLEARLY)	Expiration Date	
Signature		Date	

Please mail, fax, or email your completed registration form to:
Office of Faculty Affairs and Professional Development
University of Maryland School of Medicine
655 W. Baltimore St., Rm. 14-012 BRB, Baltimore, MD 21201 • gowens@son.umaryland.edu • Fax: 410-706-3103